Featured Research

from universities, journals, and other organizations

Bench-to-bedside asthma research to study potential biomarker

Date:
August 15, 2013
Source:
Creighton University
Summary:
A cancer biologist's chance finding during a prostate cancer study has yielded promising results for diagnosing and treating asthma. This research could result in a new biomarker for asthma as well as novel therapies.

What started as basic cancer research at Creighton University has yielded promising results for diagnosing and treating asthma -- and the National Institutes of Health (NIH) agrees, investing nearly $1.5 million in Creighton to find out more.

In a previous prostate cancer study, Yaping Tu, Ph.D., a cancer biologist and associate professor of pharmacology at Creighton University School of Medicine, studied a mouse model that was missing a specific gene, called RGS2; he believed the deleted gene would lead to prostate cancer in the animals. Though the tumors failed to develop, Tu noticed the mice had trouble breathing and were less active, similar to asthma patients. With the help of Creighton's renowned allergy and asthma researcher Thomas Casale, M.D., professor of medicine and microbiology and immunology and Chief of the Division of Allergy and Immunology, Tu soon determined the animals suffered from airway hyperresponsiveness, or a twitchiness of the airways -- a cardinal feature of asthma.

"This finding piqued our interest and made us wonder if there was a connection to human patients with asthma," says Tu. "In a small study, we were able to confirm that RGS2 is downregulated in a high percentage of patients with asthma, confirming the possibility that this may be a target for a novel gene therapy in asthma patients."

Now with a $1.44 million, four-year NIH grant, Tu and collaborators Casale and Peter Abel, Ph.D., professor of pharmacology at Creighton University School of Medicine, will take a bench-to-bedside approach to explore how the gene works in the development of airway hyperresponsiveness and whether it can be used as a diagnostic marker for asthma. Finally, the collaborators will work to develop a therapeutic approach to restore gene function, with the hope of one day applying the research to human trials.

Asthma currently affects more than 25 million Americans. There is not one cause; different patients have different triggers. The one shared trait, however, is airway hypperresponsiveness possibly related to the change to RGS2.

"Our current treatment options are similar to a lock-and-key," Casale explains. "Each drug on the market is the key to unlock and treat a different symptom or pathway important in causing asthma -- and we still haven't found all of the keys. We still have a lot of work to do, but our findings suggest that therapy targeting RGS2 gene expression might just be the master key to managing a critical component of asthma as a whole."


Story Source:

The above story is based on materials provided by Creighton University. Note: Materials may be edited for content and length.


Cite This Page:

Creighton University. "Bench-to-bedside asthma research to study potential biomarker." ScienceDaily. ScienceDaily, 15 August 2013. <www.sciencedaily.com/releases/2013/08/130815133202.htm>.
Creighton University. (2013, August 15). Bench-to-bedside asthma research to study potential biomarker. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/08/130815133202.htm
Creighton University. "Bench-to-bedside asthma research to study potential biomarker." ScienceDaily. www.sciencedaily.com/releases/2013/08/130815133202.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins